Cellaviva delivers stem cells to treat serious blood disease

April 1, 2022

Cordblood contains blood stem cells and is routinely used to treat severe diseasesof the blood and immune system. The treatment is similar to bone marrow stem celltherapy and the most common use of cord blood is sibling donation for thetreatment of childhood leukaemia.

NextCellowns the Cellaviva biobank, which has been helping pregnant parents savestem cells in connection with childbirth since 2015. The umbilical cord bloodthat is saved is the blood that remains in the placenta and umbilical cordafter the baby is born and the cord has been cut. In addition, a piece of theumbilical cord is also collected to grow connective tissue-forming stem cells.Haematopoietic stem cells can mature into all types of blood cells and immunecells, while connective tissue stem cells can mature into other tissues such ascartilage, fat and bone.

“ Thepurpose of preserving stem cells is not the saving itself, but to have rapidaccess to the highest quality stem cells in case of serious disease. Ourorganisation contributes to the development of new therapies and the expansionof treatment options for affected patients. Ultimately, it's about savinglives," says Mathias Svahn, vd NextCell.

Thecollection of stem cells from the umbilical cord does not alter the birthingprocess in any way and is risk-free. Currently, there are over 80 healthconditions with cord blood stem cells as an approved treatment option. In addition,experimental treatments using cord blood and cord tissue stem cells are beingevaluated for conditions such as cerebral palsy and type 1 diabetes. NextCellis conducting its own clinical trials with cells from donated umbilical cordsfor the treatment of type 1 diabetes and severe pneumonia caused by COVID-19.

For more information aboutCellaviva, please contact:

SofieFalk-Jansson, Commercial Director

Tel: 08-735 2010

E-mail: info@cellaviva.se

Webpage: www.cellaviva.se | www.cellaviva.dk

 

Instagram: https://www.instagram.com/cellaviva/

Facebook: https://www.facebook.com/cellavivasverige/

 

 

For more information about NextCell PharmaAB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

 

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

 

About NextCell Pharma AB

NextCell is a phase II cell therapy company withthe drug candidate ProTrans for the treatment of type 1 diabetes. The focus isto take ProTrans to market approval via a Phase III study. ProTrans is inaddition to diabetes, used in two clinical trials for Covid-19, in Örebro andMontreal (Canada). The company is in the processes of establishing its own GMPfacility for production of ProTrans. The GMP facility is expected to be readyfor production of smaller quantities of ProTrans in 2023. NextCell furthermoreowns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva,Scandinavia's largest stem cell bank for family saving stem cells fromumbilical cord blood and umbilical cord tissue with permission from the SwedishHealth and Social Care Inspectorate (IVO).

 

 

 

Download attachmentRead full press release on Cision (external link)
2025-04-25
NextCell Pharma publishes its Interim Report 2 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2025-04-24
NextCell presents detailed analysis of the administrative report from ProTrans-Young
NextCell Pharma AB’s ("NextCell" or "the Company") CSO, Lindsay Davies, has been interviewed by Flemingsberg Science regarding the analysis of the administrative topline evaluation from the older age cohort of the ProTrans-Young paediatric trial.
Read moreRead more
2025-04-23
NextCell Presents Quarterly Report
NextCell Pharma AB ("NextCell" or the "Company") invites investors, analysts and media to an investor presentation in conjunction with the publication of the Company's second interim report for the 2024/2025 financial year, on Thursday, 25 April 2025.
Read moreRead more
2025-04-15
NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward
NextCell Pharma (“the company” or “NextCell”) has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the latest results from ProTrans-YOUNG and NextCell's participation at the International Diabetes Congress in Bangkok 7-10 April. The interview is now available with English subtitles on NextCell's website https://www.nextcellpharma.com/nyheter#foretagspresentationer
Read moreRead more
2025-04-09
NextCell’s CSO elected Vice President Elect for ISCT Europe
NextCell Pharma AB ("NextCell") announces that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT). The role is a key position within the organisation’s global leadership, offering significant influence over the future direction of cell and gene therapies, both across Europe and internationally.
Read moreRead more
2025-04-07
Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young
NextCell Pharma today announces preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo. The current analysis is an administrative subgroup analysis of the first 30 randomised patients, all included within six months of diagnosis – a favourable time point, as more insulin production is typically still present and can be preserved. However, variability in disease progression is greater early after diagnosis and during puberty, which at this stage makes interpretation of the treatment effect more challenging. A clearer effect is expected over time.
Read moreRead more
2025-03-28
NextCell’s CSO Appointed to the Board of ATMP Sweden
NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been appointed to the board of ATMP Sweden. This further reinforces both her role and NextCell’s position as a key player in the development of advanced therapies, both nationally and internationally.
Read moreRead more
2025-03-19
Recognition for NextCell’s CSO from the International Society of Cell and Gene Therapy
NextCell Pharma AB ("NextCell" or "the Company") announces that its CSO, Lindsay Davies, has been asked to lead the inaugural International Society of Cell and Gene Therapy (ISCT) industry committee for Europe and has been nominated as Vice President Elect in the 2025 ISCT elections.
Read moreRead more